Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.35 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27097561 | 1.00 | CYP1A2 (0.37) | CYP1A2HRH3ALDH1A1TSHRCARM1 | |
| SCHEMBL27097567 | 0.84 | HRH3 (0.41) | HRH3CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL27097568 | 0.84 | HRH3 (0.41) | HRH3CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL27097443 | 0.84 | HRH3 (0.41) | HRH3CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL27097464 | 0.83 | NPC1 (0.45) | CYP1A2HRH3ALDH1A1NPC1KCNH2 | |
| SCHEMBL26157286 | 0.82 | SLC18A3 (0.38) | HRH3ALDH1A1CARM1PRMT6PRMT8 | |
| SCHEMBL27108809 | 0.82 | SLC18A3 (0.38) | HRH3ALDH1A1CARM1PRMT6PRMT8 | |
| SCHEMBL22906591 | 0.81 | KDM1A (0.39) | CYP1A2ALDH1A1CARM1PRMT6PRMT8 | |
| SCHEMBL27097459 | 0.81 | GNAO1 (0.42) | HRH3 | |
| SCHEMBL27097566 | 0.81 | GNAO1 (0.42) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | CYP1A2 4777/4885HRH3 3443/4885ALDH1A1 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.